410 related articles for article (PubMed ID: 2899536)
1. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
[TBL] [Abstract][Full Text] [Related]
2. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
3. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
Willoughby CP; Cowan RE; Gould SR; Machell RJ; Stewart JB
Scand J Gastroenterol Suppl; 1988; 148():40-4. PubMed ID: 2906476
[TBL] [Abstract][Full Text] [Related]
5. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
Rao SS; Dundas SA; Holdsworth CD; Cann PA; Palmer KR; Corbett CL
Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
Ewe K; Eckardt V; Kanzler G
Scand J Gastroenterol Suppl; 1988; 148():70-5. PubMed ID: 2906479
[TBL] [Abstract][Full Text] [Related]
8. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
Jewell DP; Ireland A
Scand J Gastroenterol Suppl; 1988; 148():45-7. PubMed ID: 2906477
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Rao SS; Cann PA; Holdsworth CD
Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
[TBL] [Abstract][Full Text] [Related]
10. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.
Riley SA; Lecarpentier J; Mani V; Goodman MJ; Mandal BK; Turnberg LA
Gut; 1987 Aug; 28(8):1008-12. PubMed ID: 2889648
[TBL] [Abstract][Full Text] [Related]
11. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
12. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
Birketvedt GS; Berg KJ; Fausa O; Florholmen J
Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine in childhood inflammatory bowel disease.
Barden L; Lipson A; Pert P; Walker-Smith JA
Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
[TBL] [Abstract][Full Text] [Related]
14. Tests of renal function in patients with quiescent colitis: effects of drug treatment.
Riley SA; Lloyd DR; Mani V
Gut; 1992 Oct; 33(10):1348-52. PubMed ID: 1446858
[TBL] [Abstract][Full Text] [Related]
15. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
17. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
Andreoli A; Spinella S; Levenstein S; Prantera C
Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
[TBL] [Abstract][Full Text] [Related]
18. Drug induced otalgia due to mesalazine and sulphasalazine.
Wareing M; Mitchell D
J Laryngol Otol; 1996 May; 110(5):466-7. PubMed ID: 8762319
[TBL] [Abstract][Full Text] [Related]
19. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
